Cardio-TriTest vs Autoplaque
AI Verdict
Choose Cardio-TriTest if…
Choose Cardio-TriTest if your primary care clinic requires a comprehensive, non-invasive, and early diagnostic tool for cardiovascular disease. This device is ideal for synchronizing and visually correlating multiple heart bio-signals (ECG, PCG, MCG) to provide a broad initial assessment and aid in earlier detection of potential issues.
View Cardio-TriTest →Choose Autoplaque if…
Choose Autoplaque if your cardiology or radiology department needs advanced AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is best suited for detailed risk stratification and guiding treatment decisions based on precise measurements of atherosclerotic plaque and stenosis burden.
View Autoplaque →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cardio-TriTest | Autoplaque |
|---|---|---|
| Deployment | On-premise (device) | Workstation-based post-processing application, runs on Windows or Mac OS. |
| FDA Status | Unknown | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cardio-TriTestCardio-TriTest is designed for primary care, offering a non-invasive test procedure that integrates into existing ECG workflows and can be operated by nurses or HCAs, simplifying interpretation for general practitioners. In contrast, Autoplaque is workstation-based software, which, while interactive, may imply a less integrated workflow compared to solutions designed for broader clinical use.
Clinical Value
AutoplaqueAutoplaque provides FDA-cleared, AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography, aiding in heart attack risk prediction and treatment guidance with detailed biometric information. Cardio-TriTest offers earlier and more comprehensive cardiovascular disease detection in primary care by combining three bio-signals, identifying 'Echo Diseases' often missed by standard ECGs. However, Autoplaque's precise quantitative analysis from advanced imaging offers more definitive and actionable insights for specialized patient management.
Pricing & Value
TieBoth Cardio-TriTest and Autoplaque lack transparent public pricing information, with both stating 'contact for pricing' or 'not disclosed.' This absence of specific pricing details makes it impossible to conduct a meaningful head-to-head comparison of their cost-effectiveness or overall value proposition.
Enterprise Readiness
Cardio-TriTestCardio-TriTest explicitly states it is HIPAA compliant and mentions EMR import paths, which are crucial for enterprise adoption. Autoplaque, while a workstation-based software handling DICOM data, does not explicitly specify HIPAA compliance or the availability of a Business Associate Agreement (BAA) in the provided information or search results, posing a potential barrier for large-scale enterprise deployment.
Innovation
Cardio-TriTestCardio-TriTest demonstrates significant innovation through its AI-powered 3-in-1 diagnostic device, combining and synchronizing ECG, PCG, and MCG bio-signals for visual correlation and earlier, more comprehensive cardiovascular disease detection in primary care. This multi-modal data fusion for primary care screening represents a novel approach to diagnostics. Autoplaque's quantitative analysis of coronary plaques from CT angiography is also innovative, but Cardio-TriTest's integrated bio-signal approach for broad screening stands out.
Support & Docs
TieNeither tool provides substantial public details regarding their customer support infrastructure or comprehensive documentation. Cardio-Phoenix Inc. has limited publicly available information for Cardio-TriTest beyond a general contact email, and while Autoplaque's user manual is referenced in FDA filings, no further public details on dedicated support or documentation are available.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cardio-TriTest | Autoplaque |
|---|---|---|
| Name | Cardio-TriTest | Autoplaque |
| Company | Cardio-Phoenix Inc. | Cedars-Sinai Medical Center: AIM |
| Primary Function | AI-powered 3-in-1 diagnostic device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection in primary care. | AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. |
| Key Diagnostic Modalities/Input | ECG, PCG, MCG (bio-signals) | CT angiography images |
| Key Output/Analysis | Synchronized and visual correlation of heart bio-signals, AI-powered analysis for heart disease detection | Quantitative analysis of atherosclerotic plaque, detection and characterization of coronary artery plaque, measurement of luminal stenoses, analysis of coronary anatomy and pathology |
| Categories | Cardiology AI | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Family Medicine, Internal Medicine | Cardiology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Cardio-TriTest and Autoplaque.